Lilly and Amylin Set Date and Time for Conference Call
August 25 2008 - 5:00PM
PR Newswire (US)
Companies Will Discuss Recent FDA Advisory Regarding Byetta
INDIANAPOLIS, Aug. 25 /PRNewswire-FirstCall/ -- Eli Lilly and
Company (NYSE:LLY) and Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN)
will host a conference call on Tuesday, August 26, 2008 at 5:00
p.m. EDT to discuss the recent FDA advisory on Byetta(R)
(exenatide) injection. Participating in the call for Lilly will be
Donald Therasse, M.D., vice president of global patient safety.
Participating in the call for Amylin will be Daniel M. Bradbury,
Amylin's president and chief executive officer, and Orville G.
Kolterman, M.D., senior vice president of research and development.
Investors, media and the general public can access a live webcast
of the conference call through a link that will be posted on
Lilly's website at http://www.lilly.com/ or Amylin's website at
http://www.amylin.com/ The webcast of the conference call will be
available for replay through September 26, 2008. For those without
access to the Internet, the live call may be accessed by phone by
calling (866) 814-1915 (domestic) or (703) 639-1359
(international), passcode 1277182. A replay of the call will also
be available by phone through September 26, 2008 beginning
approximately one hour after the close of the call and can be
accessed at (888) 266-2081 (domestic) or (703) 925-2533
(international), passcode 1277182. About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a
growing portfolio of first-in-class and best-in-class
pharmaceutical products by applying the latest research from its
own worldwide laboratories and from collaborations with eminent
scientific organizations. Headquartered in Indianapolis, Ind.,
Lilly provides answers - through medicines and information - for
some of the world's most urgent medical needs. Additional
information about Lilly is available at http://www.lilly.com/.
P-LLY Through a long-standing commitment to diabetes care, Lilly
provides patients with breakthrough treatments that enable them to
live longer, healthier and fuller lives. Since 1923, Lilly has been
the industry leader in pioneering therapies to help health care
professionals improve the lives of people with diabetes, and
research continues on innovative medicines to address the unmet
needs of patients. For more information about Lilly's current
diabetes products visit http://www.lillydiabetes.com/. About Amylin
Amylin Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and
commercialization of innovative medicines. Amylin has developed and
gained approval for two first- in-class medicines for diabetes,
SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide)
injection. Amylin's research and development activities leverage
the company's expertise in metabolism to develop potential
therapies to treat diabetes and obesity. Amylin is headquartered in
San Diego, California with over 2,000 employees nationwide. Further
information on Amylin Pharmaceuticals is available at
http://www.amylin.com/. (Logo:
http://www.newscom.com/cgi-bin/prnh/20040122/LILLYAMYLINLOGO )
http://www.newscom.com/cgi-bin/prnh/20040122/LILLYAMYLINLOGO
http://photoarchive.ap.org/ DATASOURCE: Eli Lilly and Company
CONTACT: Mark E. Taylor of Eli Lilly and Company, +1-317-276-5795
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024